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The study aim was to investigate the effect of endogenous insulin release on lipolysis in subcutaneous adipose tissue after adrenergic stimulation in obese subjects diagnosed with
type 2 diabetes (T2D). In 14 obese female T2D subjects, or 14 obese non-T2D controls,
glycerol concentration was measured in response to the α1,2,ß-agonist norepinephrine,
the α1-agonist norfenefrine and the ß2-agonist terbutaline (each 10−4 M), using the microdialysis technique. After 60 minutes of stimulation, an intravenous glucose load (0.5 g/kg lean
body mass) was given. Local blood flow was monitored by means of the ethanol technique.
Norepinephrine and norfenefrine induced a four and three fold rise in glycerol dialysate concentration (p<0.001, each), with a similar pattern in adipose tissue. Following agonist stimulation and glucose infusion, endogenous insulin release inhibited lipolysis in the presence of
norepinephrine, which was more rapid and pronounced in healthy obese controls than in
T2D subjects (p = 0.024 obese vs T2D subjects). Insulin-induced inhibition of lipolysis in the
presence of norfenefrine was similar in all study participants. In the presence of terbutaline
the lipolysis rate increased two fold until the effect of endogenous insulin (p<0.001). A similar insulin-induced decrease in lipolysis was observed for each of the norfenefrine groups
and the terbutaline groups, respectively. Adipose tissue blood flow remained unchanged
after the iv-glucose load. Both norepinephrine and norfenefrine diminished blood flow
slightly, but insulin reversed this response (p<0.001 over the entire time). Terbutaline alone
and terbutaline plus increased endogenous insulin augmented local blood flow (p<0.001
over the entire time). In conclusion, a difference in insulin-induced inhibition of lipolysis was
observed in obese T2D subjects compared to obese healthy controls following modulation
of sympathetic nervous system activity and is assumed to be due to ß1-adrenoceptor mediated stimulation by norepinephrine.
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Introduction
Impaired adipose tissue metabolism in obesity plays a key role in obesity-related pathophysiology with diverse metabolic consequences, including hyperglycemia and insulin resistance
[1,2]. Insulin promotes the uptake and intracellular metabolism of glucose in adipose tissue
and inhibits lipolysis. Loss of insulin’s anti-lipolytic action allows triglycerides in fat tissue to
be broken down, freeing glycerol and non-esterified fatty acids (NEFA) [3]. Increased circulating NEFA concentrations associated with increased basal adipose tissue lipolysis contribute to
peripheral insulin resistance [2,4].
The sympathetic nervous system (SNS) innervates white adipose tissue and its activation is
necessary for lipolysis [5]. SNS activity has been reported to be either decreased, normal, or
increased in obesity [6]. However, evidence has been accumulating that low sympathetic nervous system activity and reactivity and/or reduced sensitivity to sympathetic stimulation may
play a role in the development and maintenance of obesity [7]. Along with insulin, catecholamines are the major hormonal regulators of adipose tissue metabolism acting via α1,2- and ßadrenergic receptors [8–10]. In human adipose tissue, ß1-3-adrenoceptors increase lipolysis, and
the ß2-adrenoceptor seems to be especially important for lipolysis in vivo, because of its high
activity and concomitant strong stimulatory impact on adipocyte lipolysis and blood flow [11].
The ß3-adrenoceptor appears to be only a minor factor in the control of lipolysis [12]. With
regard to the α-adrenoceptor an activation of lipolysis has been reported through α1-adrenoceptors [13,14], whereas inhibition is induced via α2-adrenoceptors [5]. Catecholamines, acting
through ß-activation, inhibit insulin action in fat cells and thereby promote insulin resistance
[15]. It has been further suggested that insulin-ß-adrenoceptor interactions also occur in adipocytes. Insulin can acutely reduce cell surface ß-adrenoceptor numbers in these cells, with a subsequent decrease in the lipolytic sensitivity to beta-adrenergic agonists [16].
Metabolic differences between non-T2D obese subjects, herein referred to as healthy, and
T2D obese subjects are well established. Insulin resistance, with respect to anti-lipolysis, is
present in T2D [17,18], but to a lesser extent in obesity alone [19]. Furthermore, catecholamine
resistance to lipolysis due to impaired activity of ß2-adrenoceptors in subcutaneous adipocytes
(in vitro) from upper-body-obese males, was more pronounced in T2D than in controls [20].
This study was designed to investigate the effect of endogenous insulin on catecholaminestimulated lipolysis in the adipose tissue of obese T2D subjects compared to healthy obese controls using the well-established microdialysis technique [21].

Patients and methods
Subjects
Subjects were referred by their physicians to the University of Ulm Obesity Center for the
treatment of obesity and type 2 diabetes. They were informed about the study and asked for
voluntary participation. A flow chart of the 6-months patient recruitment is given in Fig 1.
The experimental group was composed of 14 T2D female obese subjects. Study results were
compared to 14 weight- and age-matched healthy female obese controls (control group). The
number of subjects was considered to be sufficient for the detection of blood flow changes in
adipose tissue [22]. The participants’ weight was stable for at least three months prior to the
investigations. Clinical characteristics for both groups are given in Table 1. The diabetes duration ranged from 2 to 5 years. However, it should be noted that although patient’s diabetes has
been diagnosed within these 5 years, an individual onset of the disease ahead of diagnosis cannot be excluded, conclusively early physiological changes with effects on sympathetic nervous
system cannot be ruled out either.
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Fig 1. CONSORT flow diagram of patient recruitment.
https://doi.org/10.1371/journal.pone.0173803.g001

Six T2D subjects and five controls were on anti-hypertensive medication (diuretics, Cachannel blockers). One week before the start of microdialysis experiments, all medication was
discontinued. A registered dietitian advised participants to keep a balanced isoenergetic diet
Table 1. Clinical characteristics of female study subjects.
T2D subjects (n = 14)

Controls (n = 14)

Age (years)

41.4±15.0

43.0±14.1

Systolic blood pressure (mmHg)

165.3±41.9

147.1±19.9

Diastolic blood pressure (mmHg)

94.6±16.9

91.4±12.4

Body weight (kg)

121.7±19.4

126.8±22.2

2

Body mass index (kg/m )

45.2±7.6

44.7±6.0

Percent body fat (%)

45.0±5.6

41.8±6.5

HbA1c (%)

8.1±1.4

6.4±0.3*

Blood glucose (mmol/L)

6.9±2.3

5.2±0.6*

Insulin (μU/mL)

30.5±22.0

18.6±7.0

Total cholesterol (mmol/L)

5.7±0.9

5.4±0.9

HDL-C (mmol/L)

1.1±0.7

1.3±0.4

Triglyceride (mmol/L)

3.2±4.4

1.8±0.7

Values are means ± SD
*p< 0.05 type 2 diabetic subjects (T2D) vs. healthy obese controls
https://doi.org/10.1371/journal.pone.0173803.t001
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(20% of the energy derived from nutrients was from protein, 30% from fat, and 50% from carbohydrates) and to maintain their habitual exercise scheme. The investigation has been conducted according to the principles expressed in the Declaration of Helsinki. The study was
approved by the Ulm University Ethics Committee and each participant gave written informed
consent.

Study protocol
On the day of the microdialysis investigations, participants were received at 8.00 a.m. in the
research facility after an overnight fast and handled by the study nurse. Anthropometric measures were taken and thereafter subjects remained in the supine position for the remainder of
the study. Body composition was measured by bioelectrical impedance analysis and blood
pressure was determined by auscultation.

Blood sampling procedure and glucose load
A teflon catheter was inserted into an ante-cubital vein for drawing blood samples. Venous
blood was taken at baseline for clinical characteristics and every 30 minutes thereafter for the
determination of glycerol, glucose, and insulin levels. Two hours after the start of the microdialysis experiments an intravenous (iv) glucose load was administered at a rate of 0.5 g glucose / kg lean body mass.

Microdialysis experiments
For the microdialysis experiments, four catheters (30 x 0.3 mm Cuprophane, 3000 Da cut-off,
glued onto 50 and 100 mm long sections of nylon tubing) were inserted into the abdominal subcutaneous adipose tissue of every subject without using anaesthesia, each 10 cm apart [21]. The
catheters were connected to a high-precision pump (Perfusor VI, Braun, Melsungen, Germany)
that delivered a flow rate of 2.5 μL/min and the catheters were perfused with saline buffer. For
blood flow measurement, ethanol (100 mM) was added to the perfusion solutions [22]. No dialysate was collected 45 minutes after implantation. The experiments started at time 0 minutes.
One catheter was perfused with saline constantly (240 minutes) for basal glycerol values
and for the assessment of insulin’s effect on lipolysis and local blood flow. The three other
catheters were perfused with saline for 60 minutes and thereafter with either the α1,2,ß-agonist
norepinephrine (10−4 M), the α1-agonist norfenefrine (10−4 M) or the ß2- agonist terbutaline
(10−4 M). Two hours after the start of the experiment the iv-glucose load was given.

Drugs and analytical methods
Norepinephrine was obtained from Hoechst Marion Roussel (Bad Soden, Germany), norfenefrine was purchased from Gödecke AG (Berlin, Germany) and terbutaline from Astra
Zeneca GmbH (Wedel, Germany). Glycerol concentrations were analyzed with a bioluminescence method [23]. For ethanol measurements, two consecutive samples were combined. Ethanol concentrations were determined by gas-chromatography [24]. Glucose and insulin were
measured by routine clinical methods.

Statistics
Data are presented as the mean ± SEM unless otherwise stated. Differences in clinical characteristics with normal distributed parameters of both groups were determined by Student t-test.
Differences between HbA1c and the serum lipid levels of each group were analyzed using
the Mann-Whitney-U test. For paired comparison of not normal distributed values the
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Wilcoxon’s paired test was applied. Two-way ANOVA for repeated measurement was performed to determine between groups effects as well as within subject effects and group by time
interactions. Time series data were collected for continuous variables, over time. For the comparison of intervention effects in subcutaneous adipose tissue between both groups at different
times, time series of interest were determined with (i) basal (start of measurement to minute
60), (ii) adrenergic stimulation (60–120 minutes), and (iii) iv-glucose load (120–240 minutes).
Single missing values were replaced with the mean of the observed values for that variable.
Data for blood flow statistics were only partly available from one subject in both groups. A
value of p<0.05 was considered significant. The software package SPSS version 21.0 (SPSS
Inc., Chicago, IL) was applied for statistical analysis.

Results
Fig 2 shows the changes of glucose, insulin, and glycerol concentration in the blood, when
iv-glucose infusion was given 120 minutes after the start of the microdialysis experiment.
Although the glucose concentration was higher in obese type 2 diabetic subjects under basal
conditions (F = 7.1, p = 0.013) (Fig 2A), in both groups glucose concentrations rose rapidly to
about 14 mM/L and then declined towards the baseline during the following 120 minutes. The
reduction in glucose concentration was delayed in obese diabetic subjects compared to the
controls (F = 6.6, p<0.001, interaction term). Basal insulin levels were similar in all patients;
after the iv-glucose intervention, controls released significantly more endogenous insulin
(F = 8.6, p<0.001, interaction term) (Fig 2B). Overall, in both groups insulin concentration
returned towards the baseline, but was still elevated at the end of the study period. Plasma glycerol concentrations decreased similarly in both groups after glucose administration and remained stable at a low concentration during the last 30 minutes of the experiment (F = 13.9,
p<0.001) (Fig 2C). Detailed statistical results are given in S1 File.
In the subcutaneous adipose tissue, the basal glycerol concentrations were stable until the
interventions (Fig 3A–3D). The effect of the iv-glucose load on glycerol dialysate concentration, which is a significant reduction, is shown in Fig 3A with no group difference (F = 7.5,
p<0.001).
In response to the α1,2,ß-agonist norepinephrine (Fig 3B), glycerol concentration increased
over four-fold (F = 93.5, p<0.001). The administration of iv-glucose reversed this effect, the
decline was faster in obese subjects, with a significant interaction between T2D subjects and
controls (F = 2.9, p<0.001) and hence lower glycerol levels (F = 5.7, p = 0.024). In both groups
glycerol dialysate concentration remained elevated compared to the baseline at the end of the
experiment (p<0.001 T2D and p = 0.012 controls).
The α1-agonist norfenefrine induced a similar rise in glycerol compared with norepinephrine, although to slightly lower levels (Fig 3C). However, after the highest dialysate glycerol
concentration was reached, the glycerol level declined to almost basal values after 240 min
without a difference between the T2D and control subjects. The changes in glycerol concentration during the entire study period were significant (F = 65.3, p<0.001).
The ß2-adrenoceptor agonist terbutaline (Fig 3D) induced a significant two-fold increase of
glycerol concentration and endogenous insulin decreased this outflow gradually. The change
in glycerol levels was similar in all patients during the study period (F = 44.4, p<0.001).
Detailed statistical results for glycerol changes in adipose tissue in response to the interventions are given in S1 File.
The local blood flow in the tissue surrounding the microdialysis probe was investigated by
measuring the escape of ethanol from the perfusion medium. For example, a decreased outflow
to inflow ratio across the catheter indicates increased local blood flow.
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Fig 2. Glucose, insulin and glycerol concentrations in blood after an iv-glucose load. Glucose (Fig 2A), insulin (Fig 2B) and glycerol (Fig
2C) concentrations in venous plasma of 14 obese T2D subjects (●) and 14 obese controls (). At time 120 minutes an iv-glucose load (0.5 g/kg
lean body mass) was given (dotted arrow). Data are means ± SEM, #p<0.05 time 0–120 minutes, *p<0.05 time 120–240 minutes obese T2D
subjects vs. obese controls.
https://doi.org/10.1371/journal.pone.0173803.g002

Fig 4A depicts the results of blood flow measurement under basal conditions and after the
iv-glucose load. Basal blood flow remained unchanged (F = 0.6, p = 0.71) and the iv-glucose
load induced only minor changes: notably, in the control group, a small acceleration occurred
for 30 minutes in response to the glucose load. No such effect was observed in the diabetic
patients.
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Fig 3. Glycerol microdialysate outflow in adipose tissue in response to adrenergic stimulation and after an iv-glucose load. Interstitial
glycerol concentration in the abdominal subcutaneous adipose tissue of 14 obese T2D subjects (●) and 14 healthy obese controls (). Fig 3A:
Perfusion with saline during the duration of the experiment only. Fig 3B–3D: Perfusion with saline for 60 minutes. Then norepinephrine (Fig 3B),
terbutaline (Fig 3C) or norfenefrine (Fig 3D), respectively, were added to the perfusate (solid arrow) at 10−4 M each. 120 minutes after time 0, an ivglucose load was given intravenously (0.5 g/kg lean body mass) (dotted arrow). Data are means ± SEM, *p = 0.024 time 120–240 minutes obese
T2D subjects vs. obese controls.
https://doi.org/10.1371/journal.pone.0173803.g003

Detailed statistical results for ethanol outflow changes in adipose tissue in response to the
interventions are given in S1 File.
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The effect of norepinephrine on local adipose tissue blood flow is depicted in Fig 4B. In
both groups, the catecholamine induced a decrease in blood flow, whereas the iv-glucose load
reversed this effect (F = 4.5, p<0.001).

Fig 4. Change in adipose tissue blood flow in response to adrenergic stimulation and after an iv-glucose load. Ethanol ratio representing
blood flow in the abdominal subcutaneous adipose tissue of 14 obese T2D subjects (•) and 14 obese controls (). Fig 4A: Perfusion with saline
during the duration of the experiment only. Perfusion with saline for 60 minutes and thereafter administration of norepinephrine (Fig 4B),
norfenefrine (Fig 4C) or terbutaline (Fig 4D), respectively, at a concentration of 10−4 M each (solid arrow). 120 minutes after the start of the
microdialysis experiments an iv-glucose load was given intravenously (0.5 g/kg lean body mass) (dotted arrow). Data are means ± SEM.
https://doi.org/10.1371/journal.pone.0173803.g004
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The α1-agonist norfenefrine caused blood flow changes analogous to that observed after
norepinephrine stimulation (Fig 4C). In all subjects local blood flow was inhibited initially,
whereas the iv-glucose load triggered the opposite effect (F = 5.3, p<0.001).
The ß2-agonist terbutaline (Fig 4D) exerted a stronger effect on blood vessels. The agent
alone, and even more so with the iv-glucose load, increased blood flow significantly (F = 12.4,
p<0.0001).

Discussion
In the present study, we addressed the question whether the lipolysis rate in subcutaneous adipose tissue of obese T2D subjects versus healthy obese controls is different after an iv-glucose
load and hence the endogenous insulin release upon adrenergic stimulation.
The interstitial glycerol level in adipose tissue reflects lipolysis, since glycerol, in contrast to
fatty acids, is metabolized by the tissue to an insignificant extent [25]. The iv-glucose load
decreased glycerol concentration by approximately 30% in the blood of all subjects, and similarly in the subcutaneous adipose tissue, although in the healthy obese participants much more
insulin was released. Insulin is generally considered to be the main factor in the inhibition of
lipolysis, but obesity is a well-known risk factor for insulin resistance, with increased lipolysis,
and development of T2D [26–28]. The higher insulin concentrations observed in the obese
control subjects would be expected to result in a more pronounced inhibition of lipolysis. Fat
cells respond differently to insulin, depending on factors such as their size, and a positive association has been shown between adipocyte size, fasting insulin levels and insulin resistance
(HOMA-IR) [28–30]. The participants in our study were all severely obese and therefore different insulin concentrations might not be fully effective in these enlarged fat cells under basal
conditions compared with adipocytes from lean healthy individuals. However, an interesting
finding in this study is that although baseline glucose concentration in obese T2D was higher,
after the iv-load peak glucose concentration was similar in both groups. The results suggest
that T2D patients may have a better insulin sensitivity, not insulin resistance, at least at an
acute glucose loading stimulation.
Norepinephrine perfusion induced a similar rise in adipose tissue glycerol dialysate concentration in all subjects. Catecholamine stimulation of lipolysis in nondiabetic and diabetic
humans has been investigated previously, and consistent with our results the lipolysis rate was
not different between the groups [31]. However, as we observed in this study, in response to
the iv-glucose load the glycerol concentration declined, but the reduction was faster in the tissue of healthy obese subjects. This enhanced anti-lipolytic response in the obese healthy controls could be due to the higher insulin concentration after the glucose impact, which had a
stronger effect on norepinephrine-stimulated lipolysis. In human adipose tissue catecholamines act on adipocytes via ß-adrenergic receptors, especially ß1- and ß2-receptors, and as
reported, insulin powerfully inhibits this catecholamine-stimulated lipolysis [32]. Furthermore, fat cell lipolysis is activated via α1-adrenergic receptors [13,14]. Our results show that, in
response to the α1,2,ß-norepinephrine and the α1-norfenefrine application, the glycerol concentration increased in a similar fashion. However, in the presence of norfenefrine, the reduction of the glycerol release induced by insulin was equal in all subjects. The results for the ß2agonist terbutaline and the subsequent iv-glucose application show that the course of the glycerol dialysate concentration was consistently similar in both study groups. Overall, the combined findings suggest that insulin has different effect only via the ß1-adrenergic receptors,
since after the stimulation of α1- and ß2-receptors no distinction was revealed.
The iv-glucose load and therefore insulin stimulation did not result in significant changes
of adipose tissue blood flow (ATBF) in the subcutaneous adipose tissue of the study groups. It
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has been reported in previous studies that in lean individuals, blood flow accelerates after a
glucose load, but in obesity and/or insulin-resistant subjects unaltered or lower ATBF and
blunted postprandial responses have been observed [33–35]. Nevertheless, it has been suggested that insulin does not exert a direct effect on ATBF, rather insulin might be an important
mediator, possibly acting via sympathetic activation or endothelial dysfunction [36,37]. A
mutual interference between sympathetic nervous activity and hyperinsulinemia has been
reported in lean individuals in previous investigations [38]. In our study the effect of insulin
was determined after direct stimulation of adipose tissue with adrenergic agents to reveal the
function of different adipocyte adrenoceptors. The stimulation of ß2-adrenoceptors explicitly
increased blood flow alone and then was enhanced further, although temporarily, by insulin.
Norepinephrine (and also norfenenfrine) first showed a decrease in blood flow and this effect
was reversed by insulin. Beta-adrenoceptors are predominantly regarded as regulators and
enhancers of adipose tissue blood flow [37,39]. This would mean that insulin overrides the
effect of α1-adrenoceptors via the action of ß-receptors. However, under basal conditions
blood flow did not change significantly in either group. Therefore, the insulin-induced effects
in the presence of adrenergic agents cannot be explained by their stimulation and other mechanisms may be involved [37].

Conclusions
In conclusion, the basal as well as adrenergic stimulated lipolysis rate in obese T2D subjects is
not different from healthy obese controls. However, sympathetic stimulation of lipolysis and
the anti-lipolytic response induced by endogenous released insulin are different and is merely
assumed to be caused by ß1-adrenoceptors. Blood flow changes show the influence of insulin
upon sympathetic stimulation with acceleration, but the underlying mechanisms remains to
be elucidated.

Supporting information
S1 File. Results of ANOVA for repeated measurement statistics.
(DOCX)
S2 File. Trend statement checklist.
(PDF)
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Enocksson S, Shimizu M, Lönnqvist F, Nordenström J, Arner P. Demonstration of an in vivo functional
ß3-adrenoceptor in man. J Clin Invest. 1995; 95: 2239–2245. https://doi.org/10.1172/JCI117914 PMID:
7738189

12.

Barbe P, Millet L, Galitzky J, Lafontan M, Berlan M. In situ assessment of the ß1-, ß2- and ß3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Brit J Pharmacol. 1996; 117: 907–913.

13.

Flechtner-Mors M, Jenkinson CP, Alt A, Adler G, Ditschuneit HH. In vivo alpha(1)-adrenergic lipolytic
activity in subcutaneous adipose tissue of obese subjects. J Pharmacol Exp Ther. 2002; 301(1): 229–
233. PMID: 11907178

14.

Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J. In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res. 2002; 10(6): 555–558. https://doi.org/10.1038/oby.
2002.75 PMID: 12055332

15.
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